William G. Herrington

Medicine · Health Sciences

59h-index27.5kcitations272works131.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Kidney Disease and Diabetes(59), Diabetes Treatment and Management(52), Dialysis and Renal Disease Management(45), Blood Pressure and Hypertension Studies(33), Lipoproteins and Cardiovascular Health(25)

Publications240 total

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
The Lancet·2026Open Access
In CKD, electronic letter nudges for patients or providers did not increase RASi or SGLT2i prescriptions at 6 mo
Annals of Internal Medicine·2025
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy
American Journal of Kidney Diseases·2025Open Access
Chronic kidney disease
The Lancet·2025· 7 citedOpen Access
Polygenic prediction of coronary heart disease among 130 000 Mexican adults
European Journal of Preventive Cardiology·2025· 1 citedOpen Access
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
JAMA·2025· 6 citedOpen Access
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria
JAMA·2025· 5 citedOpen Access
“Hi”s and “Lo”s of Targeting Serum Phosphate Levels in Hemodialysis
Journal of the American Society of Nephrology·2025
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis
The Lancet Diabetes & Endocrinology·2025· 5 citedOpen Access
Net Effects of SGLT2 Inhibitors by Diabetes Status and Albuminuria
Journal of the American Society of Nephrology·2025
#1267 Impact of diabetes, albuminuria, acute eGFR dip, and disease severity on the effects of empagliflozin on progression of chronic kidney disease
Nephrology Dialysis Transplantation·2025Open Access
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY
American Journal of Kidney Diseases·2025· 2 citedOpen Access
Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study
Hypertension·2025Open Access
Glucose Interference in Urine Biomarkers and Implications for Sodium-Glucose Cotransporter 2 Inhibition
Kidney International Reports·2025· 1 citedOpen Access
Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis
British Journal of Cancer·2025· 2 citedOpen Access
Estimated glomerular filtration rate, albuminuria, and risk of infection: a collaborative meta-analysis of individual participant data
EClinicalMedicine·2025Open Access
Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD
Clinical Journal of the American Society of Nephrology·2025· 1 citedOpen Access
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
EClinicalMedicine·2025· 3 citedOpen Access
Interference of urine tubular biomarker measurements by glycosuria: implications when using SGLT2 inhibitors
2025Open Access
Long-Term Effects of Empagliflozin in Chronic Kidney Disease
New England Journal of Medicine·2025
page 1 of 12Next →

Frequent Co-authors

Colin Baigent(29), Richard Haynes(25), Martin Landray(24), Jonathan Emberson(21), Natalie Staplin(16), Christoph Wanner(15), Adeera Levin(12), Christina Reith(12), David C. Wheeler(12), Rory Collins(10), Borislava Mihaylova(10), Bengt Fellström(9), Jane Armitage(8), David Preiss(8), Vera Krane(7), Alan Cass(7), Bruce Neal(7), Hallvard Holdaas(7), Michael Hill(7), Hiddo J.L. Heerspink(7)